Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer

Yu Zhao1,2,3,11, Liguow Wang6,11, Shancheng Ren9, Lan Wang1,2,3, Patrick R. Blackburn1, Melissa S. McNulty1, Xu Gao5, Meng Qiao5, Robert L. Vessella8, Manish Kohli7, Jun Zhang10, R. Jeffrey Karnes2, Donald J. Tindall2, Youngsoo Kim9, Robert MacLeod9, Stephen C. Ekker1, Tiebang Kang10, Yinghao Sun11* and Haojie Huang1,2,3*

1Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; 2Department of Urology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; 3Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; 4Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; 5Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China; 6Department of Urology, University of Washington, Seattle, WA 98195, USA; 7Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; 8Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; 9Ionis Pharmaceuticals Inc, Carlsbad, CA 92010, USA; 10Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.

Background: Androgen deprivation therapy has long been the mainstay of treatment for advanced prostate cancer, but tumors inevitably become castration-resistant prostate cancer (CRPC). Increasing evidence suggests that persistent androgen receptor (AR) signaling plays an essential role in development of hormone therapy resistance. It has been shown recently that enhancer RNAs (eRNAs) is widely transcribed from cell lineage-specific enhancers. Mechanistic studies show that in a locus-specific manner, eRNAs act in cis to stabilize enhancer-promoter looping, establish chromatin accessibility or facilitate release of the negative elongation factor (NELF) complex. Estrogen receptor (ER)- or AR-regulated eRNAs also act in trans to regulate gene expression in hormone-responsive cells, but the effects appear to be relatively infrequent in the cell types examined. To date, however, the function and disease relevance of AR-bound enhancer RNAs (AR-eRNAs) remain poorly understood.

Methods: High throughput AR ChIP-seq and strand-specific RNA-seq approaches were employed to identify AR-regulated enhancer RNAs (AR-eRNAs). 3C assays were used to verify the enhancers that express AR-eRNAs. Small interference RNAs and TALEN-mediated gene deletion were utilized to assess the functions of AR-eRNAs in gene transcription regulation and prostate cancer cell growth.

Results: We identified a group of AR-regulated enhancer RNAs (e.g. PSA eRNA) that were upregulated in CRPC cells, patient-derived xenografts (PDX) and patient tissues. PSA eRNA bound to CYCLIN T1, activated P-TEFb and promotes cis and trans target gene transcription by increasing serine-2 phosphorylation of RNA polymerase II (Pol II-Ser2p). We defined an HIV-1 TAR RNA-like (TAR-L) motif in PSA eRNA that was required for CYCLIN T1 binding. Using TALEN-mediated gene editing we further demonstrated that this motif was essential for increased Pol II-Ser2p occupancy levels and CRPC cell growth.

Conclusions: We identify a previously uncharacterized function of eRNA and a P-TEFb activation mechanism and reveal aberrant eRNA expression as a surrogate of abnormality of AR functions in CRPC that may serve as a potential therapeutic target.

Conflict of Interest: The authors declare no conflict of interest.

Funding Acknowledgements: This work was supported in part by a 2015 Movember-Prostate Cancer Foundation Challenge Award (2015CHALS18) and grants from the NIH (CA134514, CA130908 & CA193239) and Mayo Clinic Center for Individualized Medicine.